Real-time quantitative RT-PCR (RQ-PCR) is a sensitive tool to monitor minimal residual disease (MRD) in leukemic patients through the amplification of a fusion gene (FG) transcript. In order to correct variations in RNA quality and quantity and to calculate the sensitivity of each measurement, a control gene (CG) transcript should be amplified in parallel to the FG transcript. To identify suitable CGs, a study group within the Europe Against Cancer (EAC) program initially focused on 14 potential CGs using a standardized RQ-PCR protocol. Based on the absence of pseudogenes and the level and stability of the CG expression, three genes were finally selected: Abelson (ABL), beta-2-microglobulin (B2M), and beta-glucuronidase (GUS). A multicenter prospective study on normal (n ¼ 126) and diagnostic leukemic (n ¼ 184) samples processed the same day has established reference values for the CG expression. A multicenter retrospective study on over 250 acute and chronic leukemia samples obtained at diagnosis and with an identified FG transcript confirmed that the three CGs had a stable expression in the different types of samples. However, only ABL gene transcript expression did not differ significantly between normal and leukemic samples at diagnosis. We therefore propose to use the ABL gene as CG for RQ-PCRbased diagnosis and MRD detection in leukemic patients. Overall, these data are not only eligible for quantification of fusion gene transcripts, but also for the quantification of aberrantly expressed genes.
Introduction
The diagnosis and follow-up of leukemia patients has evolved from being solely based on morphological criteria in the past to increasingly based upon molecular methodologies. [1] [2] [3] [4] [5] [6] [7] [8] The development of PCR methods has resulted in a more accurate diagnosis of balanced translocations, particularly in cases of cryptic translocations, which before were only detectable by molecular methods. [9] [10] [11] Although appropriate in the diagnostic setting, standard reverse transcriptase-polymerase chain reaction (RT-PCR) methods are less suitable for the evaluation of the disease status during clinical remission, that is detection of minimal residual disease (MRD). Qualitative RT-PCR determinations were therefore only of limited value in the longitudinal follow-up of acute leukemia patients, since many of these patients became PCR negative.
Real-time quantitative PCR (RQ-PCR) has recently been introduced and allows rapid and sensitive detection of the fusion gene (FG) transcript in follow-up samples. 12 Compared to standard RT-PCR, real-time RQ-PCR enables accurate quantification of gene expression. An attractive feature of this technique is that crucial parameters such as the RNA quality and quantity can be evaluated. This is accomplished by parallel amplification of the target gene and one or more control genes (CGs), also called housekeeping or endogenous reference genes.
A suitable CG in any application of RQ-PCR analysis can be defined as a gene with a stable expression in all nucleated cells among different analyzed samples and which is unaffected by any experimental treatment. 13, 14 Furthermore, the selected gene should not present any pseudogenes, in order to avoid any genomic DNA amplification. 14, 15 An impaired amplification of CGs should be accompanied by a corresponding reduction in the quantity of target gene transcript(s). Variation in amplification would reflect variations in RNA quality, quantity and/or cDNA synthesis efficiency.
14 Thus, quantification of CG expression could be used for detecting poor quality samples, based on reference values observed in a large number of fresh samples. RQ-PCR would allow to assess an experimental sensitivity per sample, which is particularly important for PCRnegative follow-up samples.
Although the literature on RQ-PCR assays is rapidly expanding, no concerted effort related to the selection of appropriate CGs has been published so far. The choice of a CG remains a crucial issue and a consensus has still to be found. 14 To date, numerous CGs for MRD detection by RQ-PCR are still used: Abelson gene (ABL), [16] [17] [18] [19] [20] beta-actin gene (ACTB), 21, 22 beta-2-microglobulin (B2M), 16, 23, 24 glyceraldehyde-3-phosphate dehydrogenase gene (GAPDH), 16, 22, 25 porphobilinogen deaminase gene (PBGD), 26 transcription factor IID gene (TBP), 27 and 18S rRNA. 28 Inclusion of CG analysis should significantly enhance the reliability of MRD detection in leukemic patients. However, this is critically dependent upon optimization and standardization of CG and FG assays.
For these reasons, a collaborative action within the Europe Against Cancer (EAC) program was initiated involving 26 laboratories in 10 member countries. The aim of this network was to define and standardize RQ-PCR protocols suitable for measuring the levels of FG transcripts in leukemia with special reference to the selection and optimization of CGs. In this study, we focused on the selection and validation of suitable CGs for RQ-PCR assays from a large panel of normal and leukemic samples, which can be eligible not only for the quantification of FG transcripts, but also for the quantification of aberrantly expressed genes. The design and optimization of the FG RQ-PCR analysis are described in the accompanying manuscript. 29 
Materials and methods

Organization of the CG network
Our concerted action, initiated in March 1999, involved 26 laboratories from 10 European Community member countries. 29 All members of the network used the ABI PRISM 7700 sequence detection system (Applied Biosystems, Foster City, CA, USA). For the identification and validation of suitable CGs in the MRD setting, a subgroup consisting of six laboratories was formed. Test material was prepared centrally (Aarhü s, Denmark) and distributed to network members unless otherwise indicated. Details about the organization of the EAC program, optimization and standardization of the RQ-PCR protocol for the detection of the FG transcripts can be found in the accompanying manuscript 29 and web site: http://meidia.nord.univ-mrs.fr/EAC/publications.html.
Primers and probes
In the initial CG screening, a predeveloped human endogenous control plate (kindly provided by Applied Biosystems) containing primer and probe sets for 11 CGs was used as recommended by the manufacturer (Table 1) . Six additional CG primer and probe sets, designed by EAC laboratories, were analyzed: one EAC and one in-house 16 set for Abelson (ABL), one in-house 16 set for beta-2-microglobulin (B2M), two EAC sets for porphobilinogen deaminase (PBGD and PBGD2) and one in-house set for transcription factor IID (TBP) ( Table 1) . After selection, the number of CGs was ultimately reduced to three, which were subjected to further analysis ( Figure 1 and Table 2 ). Oligonucleotide primers and probes were designed employing the GUS (7q21) 11 
Figure 1
Schematic diagram of the three selected CG transcripts covered by the EAC RQ-PCR sets. ABL EAC set: ENF1003, ENPr1043, ENR1063; B2M EAC set: ENF1302, ENPr1342, ENR1362 set, and GUS EAC set: ENF1102, ENPr1142, ENR1162. The number under the primers and probes refers to their 5' nucleotide position in the gene transcript (see Table 2 ). ENF ¼ forward primer, ENPr ¼ TaqMan reverse probe, ENR ¼ reverse primer.
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Primer Express 1.0 program (Applied Biosystems) and the Oligo 6 program (Molecular Biology Insights Inc., Cascade, CO, USA). Primer and probe sets were also tested using 100 ng genomic DNA per PCR to confirm that assays were cDNA specific.
Plasmids calibrators
PCR products of ABL, B2M, and GUS gene transcripts for preparation of plasmids were amplified with respectively ABL-F (5 0 -CCT TCA GCG GCC AGT AGC-3 0 ) and ABL-R (5 0 -GGA CAC AGG CCC ATG GTA C-3 0 ), B2M-F (5 0 -CCT TGA GGC TAT CCA GCG T-3 0 ) and B2M-R (5 0 -CCT GCT CAG ATA CAT CAA ACA TG-3 0 ) and GUS-F (5 0 -CCT GTG ACC TTT GTG AGC AA-3 0 ), and GUS-R (5 0 -GTC TGC CGT GAA CAG TCC A-3 0 ). PCR conditions of the BIOMED-1 Concerted Action were used. 30 The protocol for cloning and preparation of plasmid dilutions is detailed in the accompanying manuscript. 29 For ABL and GUS plasmids, three dilutions (10 5 , 10 4 , and 10 3 copies in 5 ml) were used to calculate the standard curve. For the B2M plasmid, three different dilutions (10 7 , 10 6 , and 10 5 copies in 5 ml) were used. Corresponding coefficients of variation for Ct values were below 4% (ABL), 5% (B2M), or 3% (GUS) for all dilutions (data from all phases). Plasmid dilutions were centrally prepared initially in J Gabert's laboratory and subsequently kindly provided by Ipsogen (Marseille, France) for phase IV (see accompanying manuscript). 29 Biological material and preparation of RNA From heparinized peripheral blood (PB), bone marrow (BM), and PB stem cells (PBSC), mononuclear cells (MNC) were obtained by Ficoll-Hypaque density centrifugation. All patient sampling was performed according to protocols approved by the local ethical committees of the given institutions and/or geographical areas. The RS4;11 cell line was grown in medium RPMI1640 with 10% fetal calf serum and harvested in the exponential growth phase. RNA was extracted by routine methods in the participating laboratories employing either a TRIzol reagent (Invitrogen, Cergy, France), a RNAzol reagent (Biotech Italia, Rome, Italy) or a column-based system (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. After extraction and isolation, the RNA concentration was determined by measurement of the optical density at 260 nm and the RNA was stored at À801C until use.
RT and RQ-PCR protocols
Different cDNA protocols were initially used by the participating laboratories. During the first phases of the program, the cDNA protocol for the RQ-PCR was optimized. As a starting point, the BIOMED-1 protocol 30 was used and modified as described in the results section. For the detailed cDNA protocol, see the accompanying EAC manuscript. 29 The TaqMan 7700 machine was operated using the default RQ-PCR protocol as recommended by the manufacturer, except that the number of PCR cycles was increased from 40 to 50 and the PCR reaction volume was decreased from 50 to 25 ml. For analysis, a threshold value of 0.1 was used and a baseline was set to 3-15 for ABL and GUS and 3-10 for B2M. For a more thorough description of the TaqMan PCR protocol, see the accompanying EAC manuscript. 29 
Expression of the results
Results are relative to 100 ng of total RNA, corresponding to 5 ml (1/10th) of the RT reaction. The mean Ct value and the mean value of the log 10 of the CN for each CG were used for the statistical analysis, since CN did not show a normal distribution. Log-transformed data were subsequently converted into decimal values for presentation.
Collection of the data
The data from material distributed by the Aarhus laboratory, data from the first selection process of suitable CG and data from the multicenter prospective study were collected and analyzed in Aarhus, Denmark.
For testing of the 14 candidate CGs (17 primer and probe sets), data were obtained from (i) ABI endogenous control plate, (ii) in-house, and (iii) newly designed EAC primer and probe sets. For the ABI endogenous control plate, five laboratories tested a total of 65 different archived samples: 22 normal peripheral blood mononuclear cells (PBMNC), 15 acute lymphoblastic leukemia (ALL) (4 PB/11 BM), 15 chronic myeloid leukemia (CML) (10 PB/5 BM), and 13 AML (5 PB/8 BM) samples, which were obtained at diagnosis. This number was reduced to 53 for transferrin receptor gene (TFRC) (data partially missing for one laboratory) and 21 for 18S rRNA (data available from one laboratory only). A minimum of four normal PB and four leukemic samples was expected per laboratory. For inhouse ABL, B2M, and TBP primer and probe sets, 20 samples were tested in one laboratory: four normal PBMNC, three ALL, 
, and TBP (n ¼ 12). All these experiments were performed before having optimized the RT step and before establishing a common threshold for data analysis.
In the prospective study, fresh normal (PB, BM, or PBSC), ALL, AML, or CML (either PB or BM) samples were tested in individual laboratories for the three EAC selected CGs (Table 2) . MNC were isolated and cells were lysed (initial step of the RNA extraction procedure) on the same day as the samples were obtained. Initially, 316 samples were collected (Table 3) . Six leukemia samples were excluded because CG analysis was impossible due to a poor B2M plasmid amplification. Consequently, only 310 samples were analyzed to define reference values on the same set of samples. Information on the presence of a putative FG transcript was not available.
For the retrospective study (phase IVb), 311 archived ALL, AML, or CML samples (either PB or BM) with an identified FG transcript were tested in individual laboratories for the three EAC selected CGs, even if these laboratories were not included in the corresponding FG network (see accompanying EAC manuscript). 29 Results were collected and tabulated by the FG network leaders. Only samples with a CG Ct value within the reference range defined below were selected for the analysis. In the TEL-AML1 network, only 30 out of 57 samples were tested for GUS transcript expression. In the E2A-PBX1 network, data on B2M expression was not available for one sample.
Contributors appear in Table 3 for the prospective study or in each particular section of the accompanying manuscript for the retrospective study. 29 
Statistical analysis
The statistical analysis was performed in Marseille, France, using the SPSS 10 Software (SPSS Inc., Chicago, USA). Ct values were analyzed using nonparametric tests (Mann-Whitney test for unpaired samples or Wilcoxon test for paired samples) for the first step of CG selection since the number of tested samples per group could be low and heterogeneous.
Subsequently, Ct and CN values obtained with the three EAC selected CGs on a large number of samples were analyzed using a global linear model in order to compare each group with the others. For example, three groups (BM, PB, and PBSC tissues) in normal samples were compared. A posthoc analysis (Tukey method) was used to define subgroups with no statistically significant differences between each other (P-value at least 0.05) if more than two groups were concerned (see results on GUS CG expression in normal samples below). In addition, the CG expression was compared in fresh or archived samples according to a combination of main factors of variation: tissue (BM, PB, PBSC), leukemic (ALL, AML, or CML), and/or sample type (normal or leukemic). For example, six groups (2 Â 3) were compared by combining the tissue (PB or BM) and the leukemic type in fresh leukemic samples (see results below). The 95% range of expression, also called range of reference values, refers to the range between the 3rd and the 97th percentile for the selected gene and cell subtype according to the results of the posthoc analysis. The level of significance was set at a P-value below 0.05.
All the figures, tables, and raw data are available on-line at the following address: http://meidia.nord.univ-mrs.fr/EAC/publications.html. This web site will stay available for a long-term period, at least 5 years.
Results
cDNA synthesis protocol
The efficiency of the RT step is a critical determinant of the sensitivity of RQ-PCR assays. Therefore, the CG network aimed to optimize this part of the RQ-PCR assay. The optimal concentration of MuLV reverse transcriptase was found to be between 4 and 8 U per ml reaction and a concentration of 5 U per ml reaction was subsequently used (Figure 2a ). In addition, comparison of three different types of cDNA primers showed that random hexamers and target-specific primers gave the most efficient cDNA synthesis (Figure 2b ). Since specific primers must Table 3 Origin and type of fresh normal donor and leukemia patient samples during phase IVb Among 316 included samples, six were excluded due to a poor B2M plasmid amplification (see Materials and methods section).
Control genes for diagnosis and MRD detection by RQ-PCR E Beillard et al be designed for each gene target, generally applicable random hexamer primers were selected. Finally, increment of primer concentration was found to increase the cDNA yield. Concentration up to 125 mM was tested but a concentration of 25 mM was retained since Ct values reached the plateau phase ( Figure 2c ).
No differences between hexamers and nonamers were observed (data not shown). These conditions for performing the RT step were adopted by the EAC network in all further experiments. To evaluate the interlaboratory variation, cDNA synthesis and subsequent RQ-PCR were performed on centrally prepared and distributed material. Quantification of B2M gene transcript expression in RNA from the RS4;11 cell line diluted into Escherichia coli RNA showed variations of almost four Ct (equivalent to a 16-fold difference) between the six laboratories for the same dilution ( Figure 3) . Comparable results were also observed for ABL gene transcript (data not shown). Nevertheless, the differences in cDNA synthesis efficiencies were highly reproducible throughout the RNA dilutions and -most importantly -between genes as suggested by the parallel lines ( Figure 3 ). This indicates that although cDNA synthesis efficiency varies, CGs could be used for normalization of FG expression and thereby permit comparison of data in and between laboratories as observed in the accompanying manuscript. 29 
Selection of CGs
Criteria for selection: The CG group started with a screening of candidate CGs on normal PB and diagnostic leukemic samples using: (i) predeveloped human endogenous control plates (ABI) containing primer/probe sets for 11 commonly used CGs and (ii) six primer/probe sets available or developed during the study ( Seven aliquots of K562 cell line RNA were reverse transcribed to cDNA using 25 mM random primer and two-fold dilutions from 0.5-32 U of MMLV RT per microliter of cDNA reaction. TaqMan PCR was performed using primer sets for B2M, GAPDH, ABL, and BCR-ABL on each cDNA and the average Ct values of the four target genes in each cDNA plotted against the RT concentration. (b) Comparison of different cDNA primer types in K562 RNA: mixture of target gene specific primers (1 mM each), random hexa-mer primers (25 mM), an oligo(dT) primer (5 mM), and no primer. (c) Effect of primer concentration on cDNA yield. RNA aliquots from the cell lines K562 and REH were reverse transcribed using 5 U of MMLV RT per microliter of cDNA reaction and 1-125 mM random hexa-mer primer. The cDNA's yields were monitored by TaqMan PCR using B2M, GAPDH, and ABL. The median Cts of the three target genes in each cDNA were plotted against primer concentration. Interlaboratory reproducibility of cDNA synthesis assessed by B2M gene transcript amplification. In total, 10-fold dilutions of RS4;11 cell line RNA into E.coli RNA were prepared centrally (laboratory #1) and aliquots distributed on dry-ice to the CG group member laboratories. Each laboratory performed cDNA synthesis and TaqMan analysis. Similar results were observed for ABL gene transcript.
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CGs, the network aimed to identify at least one with a high median expression (Ct between 16.4 and 23.0) and at least one with a medium median expression (Ct between 23.0 and 29.6). These arbitrarily defined limits covered a range of two logs, since a 10-fold difference in cDNA amount is equivalent to 3.3 PCR cycles (Cts) if amplification efficiency is 100%. The lower limit was selected in order to obtain an adequate number of records for the baseline calculations and the higher limit to achieve sufficient sensitivity for sample evaluation. The selected CGs should fulfill the following major criteria: (i) absence of pseudogenes (known or identified by comparing mRNA sequences with the human genome sequence by BLAT search on http://genome.ucsc.edu), (ii) high or medium expression, excluding very high or low expression, (iii) no significantly different CG expression between normal PB samples and leukemic samples, and (iv) no significantly different CG expression between PB and BM. Minor criteria for exclusion were also identified: (i) variability within one leukemic type (AML, ALL, or CML) at diagnosis or normal PB, (ii) cell-cycledependent expression, and (iii) X-chromosomal location.
Two CGs were excluded according to their expression level: 18S rRNA and TBP tested with ABI primer and probe sets (Table 1) . Among the four highly expressed CGs (acidic ribosomal PO protein gene (PO, ACTB, GAPD, and B2M), only B2M was not known to have pseudogenes. 15, 31, 32 However, B2M expression analyzed by the ABI set differed significantly between normal and leukemic samples and between PB and BM (Po0.001 in both cases, n ¼ 65, Mann-Whitney test). Therefore, the ABI B2M set was discarded. Among the five remaining CGs with medium expression on ABI plate, three were discarded due to minor reasons: HPRT and PGK (X-chromosomal location) and TFRC (variable expression in hematopoietic cells). 33, 34 Among the six additional primer and probe sets, covering four CGs, in-house B2M RQ-PCR set appeared to be suitable since no statistically significant difference between PB and BM was observed. Comparison between normal and leukemic samples was not possible since only four normal samples were tested (see Material and methods). Among CGs with medium expression, TBP transcript amplified with the EAC set was of suitable median expression level (Ct ¼ 25.7). PBGD and PBGD2 sets exhibited a similar median Ct value (Ct ¼ 27). However, due to the presence of alternative transcriptional start sites, these PBGD sets were finally discarded. Median Ct values of the two ABL sets were not identical (Table 1) although Ct values were correlated (r ¼ 0.87, n ¼ 20). ABL EAC set was preferred since the median Ct value was lower. Additional data and figures are available on the EAC web site.
After the first selection process, the number of genes was reduced to five: ABL, B2M, CYC, GUS, and TBP (Table 1) , taking into account that ABL primer and probe sets could amplify both normal and translocated allele of BCR-ABL-positive leukemias, according to the design of the RQ-PCR set (Figure 1 ).
Variability of expression in normal PBMNC: These five initially selected CGs were subjected to further analysis using five locally prepared PB samples from normal donors in each of the six CG laboratories. RQ-PCR analysis was performed using optimized EAC RT and PCR protocols. The variations in Ct values of ABL, B2M, CYC, and GUS were comparable and all within three Ct values (Figure 4 ). Connecting lines of these four CGs were nearly parallel. Thus, variations in Ct values could be ascribed to differences in the efficiency of the cDNA synthesis and/or variation in the initial amount of RNA (see below). In contrast, the TBP gene transcript showed a variation of five Ct values (equal to 32-fold) and nonparallel sample lines, indicating larger variation in the TBP gene expression (Figure 4 ). The TBP gene was therefore excluded from further analysis.
cDNA specificity of primers/probe sets: Since primer and probe sequences used for the human endogenous control plate were not available, new primer and probe sets (EAC sets) for the CYC and GUS genes were designed and tested. Three different CYC primer/probe sets were evaluated in two laboratories and each set was found to amplify genomic DNA due to the presence of pseudogenes (data not shown). 35 Thus, CYC was excluded from further analysis.
To evaluate the risk of false positive results due to pseudogenes or fortuitous genomic homologies, the ABL, B2M, and GUS EAC primer/probe sets were tested in five laboratories on 150 genomic DNA samples (30 per laboratory) obtained from normal donors and leukemic patients. All RQ-PCR analyses for B2M and GUS were negative, whereas 7% (10/ 150) of samples were positive in the ABL RQ-PCR in three out of five testing laboratories (n ¼ 2, 3, and 5 positive results, respectively). However, Ct values ranged from 35 to 45 (data not shown) and therefore were far away from the Ct values obtained using good-quality RNA samples. Consequently, even if some remaining DNA was present in the RNA sample, this would not significantly affect the CG data. Therefore, we decided not to exclude the ABL primer set based on the lowlevel amplification of DNA. In conclusion, ABL, B2M, and GUS primer/probe sets shown in Table 2 were selected for further testing as potential candidate CGs in the EAC program.
CG expression in normal and leukemic samples
After having established the optimal conditions for the cDNA synthesis and RQ-PCR protocols and having defined the bestsuited CGs in the initial studies, the EAC network proceeded to establish the biological variation in the expression of the selected CGs in normal and leukemic samples.
Expression of the selected CGs in fresh samples: This prospective study was performed on normal donors (n ¼ 126) as well as on leukemic patients at diagnosis (n ¼ 184). Normal PBSC (n ¼ 26) were tested since MRD can also be studied in this Control genes for diagnosis and MRD detection by RQ-PCR E Beillard et al particular harvest. Contributing laboratories as well as sample type and numbers are shown in Table 3 .
In normal samples, ABL gene expression did not differ significantly between PB, BM, and PBSC (Figure 5a ). On the contrary, B2M gene expression significantly differed between the three different sample types (PB, PBSC, and BM) if analyzed using a global linear model (Po0.001, n ¼ 126). However, posthoc analysis revealed that B2M expression level in PB or PBSC samples was comparable (Figure 5b) . GUS gene expression was significantly different between the three sample types using a global linear model (Po0.001, n ¼ 126). Posthoc analysis showed that GUS expression was significantly lower in PB but not significantly different between BM and PBSC (Figure 5c ). In leukemic samples, CG expression was not significantly different between BM and PB or between ALL, AML, and CML, except for GUS expression (P ¼ 0.03, n ¼ 184) (Figure 5a-c) .
Comparison between normal and leukemic samples showed that only ABL expression did not differ significantly (P ¼ 0.21, n ¼ 310, Figure 5a ). In contrast, significant differences (Po0.001, n ¼ 310) were found for B2M and GUS expression using a global linear model (Figure 5b Reference values for CG expression in fresh normal and leukemic samples: We decided to establish reference values on fresh samples in order to evaluate the range of CG expression and subsequently to identify poor quality samples (see Material and method section). Reference values were defined by a target (median value) and two limits (3rd and 97th percentiles). Samples (6% of the fresh samples) outside this range were considered as unexpected results. Samples with a too high Ct value and consequently a too low CN were presumably degraded samples or samples containing an inhibitor, whereas samples with a too low Ct value and thus a too high CN could be related to an overestimated RNA quantification. The reference values, based on 126 normal samples and 184 leukemic samples, at diagnosis are shown in Table 4 .
In normal samples (n ¼ 126), an approximately 50-fold difference in ABL and GUS expression and up to 70-fold difference in B2M expression was found (Table 4 ). In leukemia samples (n ¼ 184), an approximately 100-fold difference in ABL and GUS gene expression and up to 500-fold difference in B2M expression was observed (Table 4) . A parametric approach using the mean value (and not the median) and two s.d.'s gave similar results to the methodology based on percentiles (data not shown). Comparison of the three CG transcripts expression in 310 fresh normal and leukemic samples: (a) ABL, (b) B2M, and (c) GUS. For normal samples, analysis was performed according to the tissue (BM, PB or PBSC); comparable expression levels were found between PB and PBSC for B2M gene transcript and between BM and PBSC for GUS gene transcript after posthoc analysis. In the upper right corner, result of the global linear model performed according to the sample type (normal, ALL, AML or CML) and the tissue. This P-value corresponds to the overall comparison between the nine groups, whereas the P-value under a specified subgroup refers to the value for this subgroup only. The black bold line corresponds to the median value. The box refers to the range defined by the 25th and the 75th percentile. A similar analysis was performed on archived leukemic samples (see Results).
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CG expression in archived samples: Data on archived leukemic samples at diagnosis (n ¼ 311) with an identified FG transcript were obtained from the FG groups (see accompanying manuscript). 29 Good quality samples were selected according to the reference values defined above, thus excluding cases with poor or no amplification of CG due to degradation or presence of inhibitors. ABL was a more restrictive CG for including samples compared to GUS or B2M (proportion of excluded samples, respectively, 11, 9, and 6%) resulting in a lower number of samples analyzed for this CG. Since in the TEL-AML1 network, only 30 out of 57 samples were tested for GUS transcript expression, result of 257 samples only were finally available for this CG.
An analysis similar to the previous one performed on fresh leukemia samples (see above) was performed. Only ABL gene transcript CN did not differ significantly between tissues and leukemia type (P ¼ 0.50, n ¼ 277) or between FG transcript groups, when BM and PB samples were merged (P ¼ 0.10, n ¼ 277, Figure 6a ). In contrast, the B2M gene transcript CN was significantly different between tissues and leukemia types (P ¼ 0.03, n ¼ 290) and between FG transcript groups (P ¼ 0.04, n ¼ 290, Figure 6b ). Also, GUS gene expression differed significantly between tissues and leukemia types (Po0.001, n ¼ 257) and between FG transcript groups (Po0.001, n ¼ 257, Figure 6c) .
Additional statistical results and additional figures using Ct values instead of CN are available on the web site.
Correlation between CGs and with the FGs: The expression level of the three CGs was always correlated (Po0.01), whatever Ct or CN values were used. The highest correlation was found between ABL and B2M (r ¼ 0.73), or GUS (r ¼ 0.72) Ct values in fresh normal samples (Figure 7a ) and between ABL and GUS (r ¼ 0.80) Ct values in fresh leukemia samples (Figure 7b) .
In archived leukemia samples, the highest correlation was found between B2M and GUS gene Ct values (r ¼ 0.67), whereas the lowest correlation was observed between ABL and GUS gene Ct values in the same samples (r ¼ 0.54), suggesting a differential degradation kinetic of these two genes. Finally, the correlation between the FG transcript expression and the ABL gene transcript expression was higher or identical to the two other EAC selected CGs (see accompanying manuscript 29 and EAC web site).
Discussion
EAC data
This multicenter study, which included 14 laboratories for the prospective study (Table 3 ) and the entire EAC group for the retrospective study (26 laboratories), aimed at selecting CGs that were applicable for RQ-PCR-based analysis of leukemia patients, both at diagnosis and during follow-up. The choice of suitable control genes has been the subject of discussion for a long time, at least in the onco-hematology field. 14, 36 In our study, we ultimately selected ABL, B2M, and GUS genes for extensive analysis of expression levels in normal samples and leukemic samples at diagnosis, after having evaluated 14 potential CGs. Despite the optimization of cDNA synthesis and RQ-PCR protocols, several crucial variables were identified resulting in insuperable interlaboratory variations.
The use of a CG for RQ-PCR detection of a FG transcript in leukemic patients appeared mandatory for different reasons: (i) to evaluate the RNA quantity and quality (degradation or presence of an inhibitor); (ii) to correct for such variations; (iii) to exclude poor quality samples and (iv) to calculate theoretical sensitivity of FG transcript detection. Based on our EAC data on CG amplification in fresh normal and diagnostic samples, we propose guidelines for interpreting the results of the FG detection. More particularly, this last point has not been consistently reported before on such a large scale. Furthermore, the data presented in this study are eligible not only for quantification of fusion gene transcripts, but also for the quantification of aberrantly expressed genes.
Our study found that the ABL gene transcript was a more reliable CG to compare diagnostic and MRD samples. 29 Firstly, ABL gene transcript was similarly expressed in normal and diagnostic samples as well as within normal samples. Secondly, the correlation between ABL gene expression and the different FGs expression was the highest observed among the three extensively tested CGs (ABL, B2M, and GUS). 29 Based on these observations, ABL transcript quantification offers two advantages. Firstly, it allows to correct for variations in RNA quality or quantity since variation of ABL and FG transcript expression are correlated. Secondly, it offers the possibility to assess the sensitivity level of the RQ-PCR experiment for the detection of a FG transcript either at diagnosis or during MRD follow-up (see also accompanying manuscript).
29 Table 4 Reference values of transcript expression level in normal and leukemia samples for the three selected CGs 
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Two objections can be raised concerning the use of ABL gene. Firstly, we were able to amplify genomic DNA with the EAC ABL set in 7% of concentrated genomic DNA, due to the relatively short size of ABL intron 2. Secondly, according to the location of an ABL primer/probe set on the gene between ABL exons 2 and 3, we can amplify both the wild-type ABL and the BCR-ABL gene transcripts. Indeed, it appears that these two points are of limited consequences. Genomic DNA contamination in an RNA sample will never be a major problem in samples with a CG Ct in the reference range, since contribution of DNA will be very minor (see results). Moreover, it has been shown that coamplification of ABL and BCR-ABL transcripts with ABL EAC RQ-PCR set leads to a limited inaccuracy for cells expressing a high level of BCR-ABL transcripts. 29 However, the calculation is correct if the quantification of BCR-ABL expression is regarded as a proportion of rearranged ABL alleles to the total number of ABL alleles (rearranged and normal). To circumvent the coamplification of both alleles, alternative ABL primer/probe sets can be employed spanning ABL exons 1b and 2 or exons 2 and 4.
18,37 Finally, we kept the RQ-PCR set on ABL exons 2 and 3 since a longer template size could reduce the efficiency of the TaqMan PCR.
The ABL gene was already introduced a decade ago as a CG for competitive PCR in BCR-ABL-positive leukemias 7, 38 and was further kept in RQ-PCR analysis as a control gene in our study as has in others. 18, 37 A recent study on CML found a highly significant correlation between cytogenetic (chromosome banding, interphasic or hypermetaphasic FISH) techniques and RQ-PCR data using ABL as CG, despite the fact that the ABL primer and probe set could amplify ABL and BCR-ABL transcripts as the EAC one. 19 These results suggest that ABL can indeed be used for diagnosis and follow-up of residual disease. Finally, accurate quantification during treatment follow-up is probably more important than a precise quantification of FG transcript at diagnosis. Thus, the coamplification of normal and rearranged ABL alleles should not be considered as a major limitation for using ABL as a control gene in RQ-PCR analysis for BCR-ABLpositive samples.
In this study, some control genes were not studied, such as the glucose-6-phosphate dehydrogenase (G6PD), because all potential CGs could not be tested. The use of the predeveloped human endogenous control plate in the first selection process was a starting point and few additional genes were added according to our previous experience on CG amplification. Therefore, the G6PD gene and others cannot be judged in comparison with ABL, B2M, and GUS. We excluded genes with known or encountered pseudogenes and X-chromosomal location of candidate genes. We did not test the real impact of gender on gene expression but the literature suggests that this criterion may not be relevant. 39 The existence of highly related homologues and/or pseudogenes was already considered as an important point for the selection of an appropriate control for RT-PCR analysis.
14 For these reasons, we excluded ACTB, CYC, GAPD, and PO genes, which were known to have a high 
B2M
B2M copies in 100 ng eq. RNA 
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E Beillard et al number of processed pseudogenes, as shown in Table 1 (Z Zhang, personal communication).
To our knowledge, only few quantitative studies on CG expression among different samples were reported. A monocentric study performed on a limited number of hematopoietic samples (four PBMNC and eight malignancies) focused on three CGs (ACTB, B2M, and PBGD). 40 The conclusions were that the B2M gene was the most suitable endogenous reference. We did not explore the stability of the transcript expression level during therapy. Indeed, too many variables should be taken into account: the timing of the sampling, the various treatments, and steps (induction/consolidation/intensification) of leukemia patients and BM regeneration. However, a similar question was raised in a study focusing on the effect of experimental treatment on housekeeping gene expression in human T helper cells. 41 Conclusions were that ACTB and GAPDH gene expression levels could change up to 17-fold (for GAPDH) according to the conditions and time of culture. Results of these two studies are in line with our findings: final selection of ABL, B2M, and GUS genes and elimination of GAPDH gene. However, they also suggest that expression levels of the three selected EAC CGs might be affected by the various therapeutic protocols and during the recovery phase after aplasia. This should be studied in the future.
We tried to estimate the variations of CG expression observed in routine conditions on fresh samples. We found that samples with an ABL value within the reference range, respectively, 1.3 Â 10 3 -1.3 Â 10 5 copies or Ct between 21.9 and 29.3, should be considered as an amplifiable sample and could be qualified for subsequent analysis (Table 4) . However, such limits might differ according to the RQ-PCR protocol and to the technology of PCR machines. Samples in our study with a higher CG CN (or a lower Ct value) than expected could be qualified for subsequent analysis, although only 3% of normal samples are supposed to exhibit such a result, which could probably be related to an analytical problem. On the other hand, samples with a lower CG CN (or higher Ct value) than expected are supposed to be poor quality samples and should be rejected, since only 3% of normal samples would present such values. Nevertheless, if those samples are kept for subsequent analysis, precautions should be taken for interpreting negative MRD results in these poor quality samples. Furthermore, in these samples the kinetics of degradation may be different between the FG and the CG transcripts, resulting in an over-or underestimation of MRD levels. The stability of CG and FG transcripts is currently under investigation within our EAC network (van der Velden et al, manuscript in preparation).
Quantification of CG and FG transcripts in archived diagnostic samples showed that the FG expression was correlated with the expression of the three CGs. 29 In such samples, we could correct variations in RNA quality/quantity using a ratio FG CN/CG CN, also called normalized copy number (NCN), or using DCt method by amplifying in parallel a suitable CG. 29 Furthermore, we showed that amplification of CGs greatly improved the quantification of FG transcripts in diluted samples. We observed that variations in CG expression within the reference range could reflect variations in experimental sensitivity. We will therefore propose two formulas to calculate the sensitivity of the RQ-PCR experiments both at diagnosis and during follow-up, based on CG quantification (see below).
Proposals for calculation and presentation of MRD results
The use of CGs as internal reference in an MRD setting has the potential to detect poor-quality samples as well as to correct for cDNA synthesis efficiency, thus allowing reproducible quantification of FG transcript in diagnostic and follow-up samples. However, it also offers the possibility to quantify the sensitivity of experiments, which is a crucial point for FG negative results. An important aim of the EAC network was to develop algorithms to express data in a fashion that is intuitively understandable but which also highlights the differences in day-to-day sensitivity Correlation between the three EAC selected CGs: (a) in fresh normal, (b) leukemia samples. Results appeared globally more widespread in leukemia samples compared to normal samples. This observation could be related to the increased number of samples (184 vs 126) and laboratories (14 vs 6) included, and to an effective heterogeneity of CGs expression. All P-values are below 0.01 (Po0.01).
Control genes for diagnosis and MRD detection by RQ-PCR E Beillard et al encountered when a patient is followed longitudinally during cytoreductive treatment. Based on the quantification of CG expression in a patient's follow-up samples and FG and CG expression in the patient's diagnostic sample, we propose two methodologies for calculation of MRD results and experimental sensitivity: the NCN and DDCt method. Results can be calculated either using slopes and intercepts from previously generated plasmid standard curves (DDCt method) or by employing normalized copy numbers (NCN method), where plasmid standards are always tested on each PCR plate.
The DDCt method: In the DDCt method, the Ct of the FG (Ct FG ) obtained during follow-up is first normalized by subtracting the Ct of the CG (Ct CG ) and subsequently normalized by the DCt DX , that is, (Ct FG ÀCt CG ), of the patient at diagnosis. The resulting MRD value (MRDv) and the day-to-day sensitivity value (SENSv) of the assay can then be determined from the equations appearing in Table 5 . The DDCt method is based on the assumption that intercepts and slopes are identical between FG and CG. No difference was found between FGs and CGs plasmid standard curves in the accompanying manuscript. 29 Thus, average intercept and slope values of 40 and À3.4, respectively, can be used for calculation (Table 5 ). However, if differences were to be seen, the intercept and slope of the FG should be used, since the CG Ct should be within the window of the reference values and therefore only have a minor impact on the calculation. The DDCt method, which employs Ct values, does not include any plasmid or RNA standard curve, reducing the risk of contamination, degradation, and batch variation from these.
The NCN method: In the NCN method, the MRD value is a ratio between the CG normalized expression of the FG in follow-up (FG CN /CG CN ) FUP and diagnostic samples (FG CN / CG CN ) DX (Table 5) . SENSv is calculated according to the relative expression of the FG at diagnosis (FG CN /CG CN ) DX and CG expression (CG CN,FUP ) in follow-up sample (Table 5 ). Since the NCN method makes use of standard curves, the SDS software may perform the calculation of CN. In this manuscript, we reported the use of plasmid-based standard curves, but other standard curves (eg cell line dilutions) might be used (see accompanying manuscript). 29 At least three plasmid standard dilutions should be employed for each gene to ensure proper standard curves. This methodology has the advantage that degradation of probes can be compensated for and that data generated on different types of RQ-PCR machines can be compared. However, this methodology suffers an increased cost per sample.
For calculation of MRD value, EAC data for the corresponding FG at diagnosis can be used if patient value at diagnosis is not available. Sensitivity (SENS) of the experiment can be expressed as 10 SENS (ex: 10 À5 ) and should be calculated as follow: SENS ¼ log 10 (SENSv) (see also accompanying manuscript). 29 Data presentation: With NCN or DDCt method, MRDv and SENSv values can be plotted on a graph for presentation of MRD data ( Figure 8 ). Both lead to a common presentation, for which results of follow-up samples are expressed relative to the patient's sample at diagnosis. Results can be depicted graphically with a time-scale on the x-axis, whereas day-to-day sensitivity calculated from CG values and MRD results are plotted on the y-axis. The diagnostic value is set at 1 (or 100%), independently of the FG expression at diagnosis which is nevertheless taken into account to calculate sensitivity in followup samples.
The advantages of this scale are that calculations are simpler, since only one equation is needed per FG setup. More importantly, the FG expression in different patients may be compared during follow-up, which would be highly relevant for CML patients who may show differences in the FG level at diagnosis. 37 On the other hand, when using this scale, information concerning variability of FG expression per patient 
Figure 8
Longitudinal MRD monitoring of an MLL-AF4-positive patient using EAC MLL-AF4 and ABL RQ-PCR sets. Time 0 was diagnosis, Time 12 was cytological relapse. The value at diagnosis is 1 (100%) and subsequent FG positive results are expressed relatively to diagnostic sample. At 4 months after diagnosis, the PB sample was clearly degraded (ABL Ct value: 32.3, ABL CN: 257). Although result appears in the figure, care should be taken for interpreting this negative result. The gray area defines a zone in which the minimal residual disease cannot theoretically be detected by RQ-PCR according to the value of the CG amplification at the time point. The lower the frontier between the white and the gray zone, the better the sensitivity. Calculation was performed according to DDCt and NCN methods found in Table 5 . Raw data corresponding to the amplification of the CG and the FG can be found on the EAC web site. Both methods of calculation lead to similar results either for MRD value or for sensitivity, consequently only one graphic is shown.
Control genes for diagnosis and MRD detection by RQ-PCR E Beillard et al at diagnosis is lost. A more exhaustive discussion concerning the expression of results and the choice of a standard curve can be found in the accompanying manuscript. 29 Since MRD results are expressed relative to the diagnostic value, MRDv should be below 1 in follow-up samples. Each time MRD is undetectable, only the point corresponding to the sensitivity appears. An example for longitudinal monitoring of an MLL-AF4-positive patient is shown in Figure 8 . Both methods of calculation lead to similar results either for MRDv or SENSv results, therefore only one graph is shown.
Conclusions
Our EAC program selected the most suitable CGs for RQ-PCR experiments in assessing MRD in leukemic patients and defined reference values for CG expression. To our knowledge, this is the first multicenter study of this scale (number of laboratories, number of tested samples) attempting to evaluate candidate control genes for RQ-PCR experiments. These EAC data should serve as gold standard for laboratories using the EAC protocol for the clinical implementation of RQ-PCR delineated in this and the accompanying report. 29 Furthermore, these data are eligible not only for quantification of FG transcripts, but also for the quantification of aberrantly expressed genes. However, each laboratory should be able to define its own normal range and compare it to these reference values.
We conclude that the initial promise of revolutionizing MRD detection by this method seems to be within reach due to the exceedingly high reproducibility and robustness of the RQ-PCR method. The inclusion of CGs to correct for sample variations seems to make the method applicable for gene transcript detection, thus creating a platform for future studies, where RQ-PCR assays should be crucial to assess therapeutic efficiency of classical and innovative treatment approaches, notably for inhibitors of protein tyrosine-kinases, phosphatidyl-inositol-3-kinase or farnesyl-transferase proteins.
